Objective: To investigate the prevalence and implication of cytochrome P450, family 2, subfamily C, polypeptide 9 (CYP2C9) variants and vitamin K epoxide reductase complex, subunit 1 (VKORC1)-1639 G > A polymorphisms in Chinese patients receiving warfarin therapy. Methods: Chinese Han patients requiring oral warfarin therapy were consecutively enrolled. Correlations between CYP2C9*1, *2, *3, *4, *5 variants and VKORC1-1639 G > A polymorphisms, fourth-day international normalized ratios (INRs) and warfarin maintenance dose were investigated. Results: Out of 101 patients, there were no significant differences in fourth-day INR or warfarin daily maintenance doses between patients with CYP2C9*1*1 and CYP2C9*1*3 genotypes. Patients with the VKORC1-1639 AA genotype had a higher fourth-day INR (1.87 AE 0.14) than those with the VKORC1-1639 AG genotype (1.32 AE 0.15). Warfarin maintenance dose for patients with the VKORC1-1639 AA genotype (2.40 AE 0.70 mg/day) was significantly lower than for patients with the VKORC1-1639 AG genotype (4.83 AE 0.70 mg/day). Conclusions: Unlike Caucasian populations, VKORC1-1639 G > A polymorphisms in the Chinese population may be the dominant genetic factors associated with warfarin response variability.
Introduction
Warfarin is the most widely prescribed anticoagulant drug for the prophylaxis and treatment of patients with venous and arterial thromboembolic disorders. 1 Management of warfarin therapy is problematic, however, for a number of reasons: first, since it has a narrow therapeutic index, frequent assessment of blood prothrombin time using the standardized international normalized ratio (INR) is essential to decrease the risk of bleeding, which is the most common and dangerous warfarinrelated complication; 2,3 secondly, patients exhibit large interindividual and interethnic variability in dose response to the anticoagulant effects; 4 thirdly, there are no fixed doses in relation to warfarin treatment, as dose requirements are affected by the patients' weight, diet, age, disease state, concomitant use of other medications and genetic factors. 5 Cytochrome P450, family 2, subfamily C, polypeptide 9 (CYP2C9) and vitamin K epoxide reductase complex, subunit 1 (VKORC1) are the two most important enzymes in the pharmacokinetic and pharmacodynamic pathways of warfarin. [6] [7] [8] [9] [10] [11] Compared with the wild type, variants in the genes encoding these proteins have shown impaired metabolic capacity to warfarin. 12 The aim of the present study was to investigate variants of CYP2C9, and VKORC1-1639G > A promoter polymorphisms in Chinese patients with different indications for warfarin therapy, to evaluate the contribution of genetic factors combined with demographic factors to warfarin dose variability.
Patients and methods

Study population
Chinese Han patients attending Peking University First Hospital, Beijing, China, between November 2009 and March 2011, were sequentially enrolled. Indications for warfarin treatment comprised atrial Ebrillation, valve replacement, pulmonary embolism, deep vein thrombosis, stroke and atrial flutter. Exclusion criteria included concurrent use of drugs known to interfere with warfarin, impaired hepatic function or renal function, thyroid disease, malignancy or history of radiation therapy, and age <18 years. The target range for the INR was 1.8-3.0. The initial loading dose of warfarin was 3 mg per day for the first 3 consecutive days. The first INR was determined on the fourth day of treatment and subsequently twice a week, and the dose was adjusted according to the findings. Complete warfarin dosing information was retrieved from medical records to determine the warfarin maintenance dose, defined as the dose relating to the average of three INR measurements within the target range over a minimum period of 4 weeks. Demographic data including sex, age, weight and height were recorded, in addition to indications for warfarin therapy, concomitant diseases, and concurrent medications. An antecubital venous blood sample (4 ml) was taken from each patient on arrival at the clinic. Blood samples were immediately transferred to the laboratory and stored at À20 C prior to DNA extraction.
Peking University First Hospital Ethics Committee approved the study, and all participants provided written informed consent.
Genotyping VKORC1-1639G > A and CYP2C9 variants Genomic DNA was isolated from blood leukocytes using the Wizard Genomic DNA purification kit (Promega, Madison, WI) according to the manufacturer's instructions.
The VKORC1-1639 G > A polymorphisms were detected using polymerase chain reaction (PCR) followed by digestion with the restriction enzyme Msp1 (Promega, Madison, WI, USA). PCR was performed using a commercially available kit (PCR MagiMix 2.0, Tiandz, Beijing, China) including 1 ml (38 ng) genomic DNA and 1 U AmpliTaq Õ DNA polymerase, in a final reaction volume of 25 ml, with the following primers: forward, 5 0 -GCCAGCAGGAGA GGGAAATA-3 0 and reverse, 5 0 -AGTTTG GACCTACAGGTGCCT-3; the molar concentration of the primer pairs was 10 mmol/l. Thermal cycling conditions (Mastercycler Pro, Eppendorf AG, Germany) comprised an initial denaturation at 94 C for 5 min, followed by 35 cycles of denaturation at 94 C for 30 s, annealing at 58 C for 30 s and elongation at 72 C for 30 s, with a final extension period at 72 C for 10 min. 10 ml of PCR product was digested with 0.3 ml of restriction enzyme Msp1 (made up to 20 ml with deionized water) for 2 h at 37 C. The 290 base-pair (bp) products were separated on 2.5% agarose gels, stained with ethidium bromide, and visualized under UV light.
The CYP2C9 variants were analysed using primers designed with Primer Premier software, version 3.0 (Premier Biosoft International, Palo Alto, CA, USA). The CYP2C9*2 allele was detected using PCR followed by digestion with the restriction enzyme AvaII (Promega). PCR was performed in a 25 -ml final reaction volume comprising 1.5 mM MgCl 2 , 10 mM Tris-HCl, 50 mM KCl, 10 mM dNTPs, 1 U AmpliTaq Õ DNA polymerase (Beijing Transgen Biotech, Beijing, China) and $100 ng of human genomic DNA, using 0.32 mM each of the following primer pairs: forward, 5 0 -TGCCTGTTTCAGCATCTGT C-3 0 and reverse, 5 0 -CCCCTGAAATGTTT CCAAGA-3 0 . AmpliEcation conditions comprised an initial denaturation at 94 C for 5 min, followed by 35 cycles of denaturation at 94 C for 30 s, annealing at 58 C for 30 s and elongation at 72 C for 30 s, followed by a final extension period at 72 C for 10 min. Following PCR, 10-ml aliquots of PCR product were incubated at 37 C for 2.5 h with 2.4 U of AvaII. Digested products (258 bp and 129 bp) were then separated by electrophoresis using a 2.5% agarose gel, stained with ethidium bromide and visualized under UV light.
The CYP2C9*3, *4, and *5 alleles were detected using DNA sequencing. PCR was performed in a 50 -ml final reaction volume comprising 1.5 mM MgCl 2 , 5 mM Tris-HCl, 50 mM KCl, 10 mM dNTPs, 1 U of AmpliTaq Õ DNA polymerase (Beijing Transgen Biotech) and 100 ng human genomic DNA, using 2.5 ml each of the following primer pairs: forward, 5 0 -GAACGTG TGATTGGCAGAAA-3 0 and reverse, 5 0 -T CGAAAACATGGAGTTGCAG-3 0 ; the molar concentration of the primer pairs was 10 mmol/l. AmpliEcation conditions comprised an initial denaturation at 94 C for 5 min, followed by 35 PCR cycles of denaturation at 94 C for 30 s, annealing at 54 C for 30 s, and elongation at 72 C for 30 s, followed by a final extension period at 72 C for 10 min. DNA sequencing was performed using an ABI PRISM Õ 310 Genetic Analyzer (Applied Biosystems, Foster City, CA, USA) according to the manufacturer's instructions.
Statistical analyses
Allele frequencies were estimated by gene counting. Departure from Hardy-Weinberg equilibrium was tested using 2 -test with one degree of freedom. 2 
Results
Patient demographics and genotype
A total of 101 Chinese Han patients were included in this study (Table 1) . Genotype distribution is presented in Table 2 . The frequencies of the alleles were as follows: VKORC1-1639 G allele, 0.099; VKORC1-1639 A allele, 0.901; CYP2C9*1 allele, 0.975; CYP2C9*3 allele, 0.025. No deviation from the Hardy-Weinberg equilibrium was observed in VKORC1-1639 G > A and CYP2C9 genotypes. The CYP2C9*2,*4,*5 variants were not detected in any of the participants. The majority of the study population was homozygous for the CYP2C9*1*1 genotype, while the remainder were heterozygous for the CYP2C9*1*3 genotype ( Table 2 ). Of 96 homozygous CYP2C9*1*1 patients, 77 were homozygous for VKORC1-1639 AA, 18 were heterozygous for VKORC1-1639 AG and one was homozygous for VKORC1-1639 GG. The five heterozygous CYP2C9*1*3 patients were all homozygous for VKORC1-1639 AA. For statistical comparisons between the VKORC1 genotype groups, data from one homozygous VKORC1-1639 GG patient were excluded. There were no significant differences in age, sex, height or weight between the CYP2C9 genotype groups or between the VKORC1 genotype groups.
Relationship between genotype and fourth-day INR value
Patients with the homozygous VKORC1-1639 AA genotype exhibited a mean INR of 1.87 AE 0.14, which was significantly higher than the INR observed in patients with the Figure 1A ). These results were not altered by the exclusion of five patients with a CYP2C9*1*3 genotype from analysis of the fourth-day INR in the VKORC1 genotype group. There was no significant difference in mean INRs between the CYP2C9*1*1 and CYP2C9*1*3 groups (INR ¼ 1.76 AE 0.26 and 1.93 AE 0.19, respectively). These results were not altered by the exclusion of 18 patients with the VKORC1-1639 AG genotype from analysis of the CYP2C9 genotype group ( Figure 1B) . No significant relationship was found between the factors of sex, age, height, weight, indications for warfarin treatment and the fourth-day INR (Spearman's rank correlation coefficient test). VKORC1 genotype was found to be the only factor that influenced the fourthday INR, accounting for 46.3% of INR variability (R ¼ 0.685, R 2 adj ¼ 0.463, P < 0.001, multiple linear analysis).
Relationship between genotype and warfarin daily maintenance dose
The median warfarin daily maintenance dose requirement was significantly higher in patients with the VKORC1-1639 GA genotype compared with the VKORC1-1639 AA genotype (4.83 AE 0.70 mg versus 2.40 AE 0.70 mg, respectively, P < 0.001). This result was not significantly altered by the removal of five patients with the CYP2C9*1/*3 genotype from the analysis of warfarin daily maintenance dose in the VKORC1 genotype group ( Figure 1C ). There was no significant difference in warfarin daily maintenance dose between the CYP2C9*1*1 and CYP2C9*1*3 groups (median maintenance dose 3.00 mg versus 1.88 mg, respectively). This result was not altered by the removal of 18 patients with the VKORC1-1639 AG genotype from the analysis of the CYP2C9 genotype group ( Figure 1D ).
Multivariate analysis
Using stepwise regression analysis, VKORC1-1639 polymorphism (P < 0.001), weight (P < 0.001) and age (P ¼ 0.019) were shown to have independent and significant effects on the variability in warfarin maintenance dose (Table 3) : Combined, these three factors accounted for 70.1% of the overall interindividual variability in warfarin daily maintenance dose in Chinese patients (R ¼ 0.844, R 2 adj ¼ 0.701, P < 0.001). CYP2C9 variants, height, sex and indications for warfarin treatment were not found to have significant effects on the variability in warfarin maintenance dose.
Discussion
Warfarin, a coumarin derivative first introduced in 1954, remains the predominant oral anticoagulant available for long-term use. 13 Some patients require higher-than-expected doses of warfarin to increase their INR into the therapeutic range. This phenomenon can be attributed to acquired (poor compliance, drug interactions, dietary interactions) or hereditary factors. [14] [15] [16] The present study aimed to determine whether previously identified SNPs, known to alter the pharmacokinetics and pharmacodynamics of warfarin, were associated with patients' response to warfarin according to INRs.
The main allelic polymorphisms known to be involved in warfarin metabolism are those associated with CYP2C9 and VKORC1-1639. 17 The authors' primary concern was to understand how the frequency and degree of these polymorphisms influences response to warfarin in the Chinese population. Ethnic differences in frequencies of VKORC1-1639G > A and CYP2C9*2, *3, *4 and *5 alleles are already known to exist. 2 Distinct from Caucasian populations, the frequency of the VKORC1-1639 GG genotype is 0-2%, the GA genotype $18%, and the AA genotype $80% in the Chinese population. 18 The frequency of the CYP2C9*1*1 genotype is reported to be $95%, the *1*3 genotype $5% and the *3*3 genotype 0% (i.e., not present).The *2,*4 and *5 variants have also been reported as being absent in the Chinese population. 19 The VKORC1-1639 AA genotype is widely distributed in the Chinese population, and the allele frequency of VKORC1-1639 G > A in the present study corresponded with that published elsewhere. 17 Allele frequencies of the CYP2C9 gene in the present study were consistent with those previously reported. 17, 19 The initial phase of anticoagulation treatment is the most challenging step, since the optimal dose for any patient is uncertain and the dosing is often given empirically, engendering a high risk of over-anticoagulation or haemorrhagic events. 20, 21 The major finding of the present study was that VKORC1-1639 SNPs, rather than CYP2C9 variants, affect the early response to warfarin. Patients with the VKORC1-1639 AA genotype had a significantly higher INR than those with the VKORC1-1639 AG genotype, and correspondingly, the warfarin daily maintenance dose was lower in the VKORC1-1639 AA group than in the VKORC1-1639 GA group. In the present study there was no difference between the CYP2C9*1*1 and *1*3 groups, however, in terms of INR or warfarin daily dose requirements. Although the CYP2C9*2 and *3 polymorphisms are found in 20% of the Caucasian population, only 6-10% of warfarin interindividual variability can be attributed to these two genotypes. 22 In the present study, the influence of the VKORC1-1639 G > A polymorphism is clearly suggested by the initial stage of warfarin response, and the sustained response, in Chinese patients.
The authors understand that drug resistance is a complex phenomenon involving many environmental and genetic factors. To assess whether demographic factors contributed to patients' response to warfarin, multiple logistic regression analysis was performed in the present study. Using a stepwise method, VKORC1-1639 G > A SNP, age and weight were revealed as factors associated with interindividual variability in the daily warfarin dose. Although CYP2C9 genetic variants have been recognized as key factors affecting daily warfarin dose in other research, 23 this was not the case in the present study. This discrepancy between results may be due to the fact that: (I) allele frequency of the CYP2C9*3 genotype, which affects CYP2C9 enzyme activity, is too low to cause significant distinction in the Chinese population, and (II) the sample size of the present study population was not sufficient to detect significant differences. In August 2007, the American Food and Drug Administration (FDA) approved a labelling change for warfarin that described the reported effects of VKORC1 and CYP2C9 on dose requirements, stating that 'lower initiation doses should be considered for patients with certain genetic variations in CYP2C9 and VKORC1 enzymes'. The FDA also encouraged clinical tests for these genetic variants before initiating warfarin therapy. 24, 25 The dose and administration of warfarin must be individualized according to the particular patient's genetic background. The present study suggests that specific recommendations should be made for the Chinese population, since the VKORC1-1639 G > A SNP might be the dominant genetic factor associated with warfarin response variability in Chinese patients. In order to reduce haemorrhagic complications while obtaining the appropriate INR for antithrombolytic effects in Chinese patients with the VKORC1-1639 AA genotype, the initial and maintenance doses of warfarin should be lower in relation to patients with the VKORC1-1639 AG genotype, compared with those who have other genotypes. In the Chinese population, the CYP2C9 genotype may have a much smaller role in the metabolism of warfarin than the VKORC1 genotype. In order to further verify these results via a large-scale prospective study, it may only be necessary to assess the VKORC1-1639 SNP in the Chinese population, hence saving the cost of assessing CYP2C9 variants.
A limitation of the present study is the relatively small sample size. Despite this, the authors consider the present study to be a valid attempt to evaluate the interindividual variability of warfarin maintenance dose in Chinese Han patients. The present results require further independent validation using a larger sample size and the authors plan to investigate a larger patient cohort in future.
In summary, the present study findings show that the distribution of CYP2C9 and VKORC1-1639 G > A genetic polymorphisms in Chinese Han patients differ from those reported for Caucasian populations. In the Chinese population, VKORC1-1639 G > A polymorphisms may be the dominant genetic factors associated with variability in warfarin response.
